Molnupiravir for the Treatment of COVID-19. Information for Health Professionals
Fecha
2022Número de documento
PAHO/HSS/MT/COVID-19/22-0021
Metadatos
Mostrar el registro completo del ítemOtros idiomas
Resumen
The Pan American Health Organization presents this information sheet with recommendations on the use of molnupiravir addressed to health professionals. Molnupiravir is a prodrug that significantly inhibits SARS-CoV-2 replication. It is used for the treatment of mild and moderate COVID-19 in patients who are at high risk of complications, and has shown a significant reduction in the rate of hospitalization or death of patients with COVID-19.
Colecciones
Esta leyenda debe conservarse, junto con la URL original del artículo.Attribution-NonCommercial-ShareAlike 3.0 IGO
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Pan American Health Organization; Health Systems and Services (HSS) (PAHOUnited StatesWashington, D.C., 2022)The Pan American Health Organization presents this information sheet with recommendations on the use of molnupiravir addressed to patients. Molnupiravir is a prodrug that significantly inhibits SARS-CoV-2 replication. It ...
-
Pan American Health Organization; Evidence and Intelligence for Action in Health (EIH) (PAHOUnited StatesWashington, D.C., 2022)Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression ...
-
Organización Panamericana de la Salud; Health Systems and Services (HSS) (OPSUnited StatesWashington, D.C., 2022)La Organización Panamericana de la Salud presenta esta ficha informativa con recomendaciones sobre el uso del molnupiravir dirigidas a los profesionales de la salud. El molnupiravir es un profármaco que inhibe de manera ...